Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib Oral Solution vs Tablet Bioequivalence Study
NCT04111614Phase 1Completed
- Sponsor
- Pfizer
- Start
- Oct 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tofacitinib oral solution in rheumatoid arthritis (RA), psoriatic arthritis (PsA), ulcerative colitis (UC) and 2 more (2 arms), sponsored by Pfizer. Primary endpoints: Area Under the Curve to Infinity and Area Under the Curve to Last Quantifiable Concentration. Started Oct 2019; status: completed.
02
Drugs
tofacitinib oral solution
03
Conditions
rheumatoid arthritis (RA)psoriatic arthritis (PsA)ulcerative colitis (UC)juvenile idiopathic arthritis (JIA)ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT04111614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04111614.